Bibliography
- Ehrlich P . On immunity with specific reference to cell life. Proc. R. Soc. Lond.66, 429 (1900).
- Kohler G , MilsteinC. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature256, 495–497 (1975).
- Chang JT , CarvalhoC, MoriSet al. A genomic strategy to elucidate pathways of oncogenic signaling networks. Mol. Cell 34, 104–114 (2009).
- Herlyn DM , KoprowskiH. Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int. J. Cancer27, 769–774 (1981).
- Barriere J , FischelJ, FormentoPet al. Cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) against tumor cell lines characterized for EGFR expression and K-ras mutation. J. Clin. Oncol. 27(Suppl.), (2009) (Abstract e14583).
- Thorpe PE , RossWCJ. The preparation and cytotoxic properties of antibody–toxin conjugates. Immunol. Rev.62, 119–158 (1982).
- Senter PD . Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol.13, 235–244 (2009).
- Pohlman B , SweetenhamJ, MacklisRM. Review of clinical radioimmunotherapy. Expert Rev. Anticancer Ther.6, 445–461 (2006).
- Yan L , HsuK, BeckmanRA. Antibody-based therapy for solid tumors. Cancer J.14, 178–183 (2008).
- Chen S , YuL, JiangCet al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol. 23, 1538–1547 (2005).
- Yan L , EhrlichPJ, GibsonR, PickettC, BeckmanRA. How can we improve antibody-based cancer therapy? Monoclonal Antibodies1, 67–70 (2009).
- Beckman RA , WeinerLM, DavisHM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer109, 170–179 (2007).
- Gibson CR , SandhuP, HanleyWD. Monoclonal antibody pharmacokinetics and pharmacodynamics. In: Therapeutic Monoclonal Antibodies: from Bench to Clinic. An Z (Ed.). John Wilet & Sons, Inc., Hoboken, NJ, USA 439–460 (2009).
- Sedlacek HH , SeemannG, HoffmannDet al. Antibodies as Carriers of Cytotoxicity. Karger, Basel, Switzerland (1992).
- Jain RK . Physical barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res.50, 814s–819s (1990).
- Gutmann R , LeunigM, FeyhJet al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 52, 1993–1995 (1991).
- Nugent LJ , JainRK. Extravascular diffusion in normal and neoplastic tissues. Cancer Res.144, 238–244 (1984).
- Gerlowski LE , JainRK. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res.31, 288–308 (1986).
- Clauss MA , JainRK. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res.50, 3487–3492 (1990).
- Netti PA , BerkDA, SwartzMA, GrodzinskyAJ, JainRK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res.60, 2497–2503 (2000).
- Clauss MA , JainRK. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res.50, 3487–3492 (1990).
- Melkko S , HalinC, BorsiL, ZardiL, NeriD. An antibody calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor-targeting performance. Int. J. Radiat. Oncol. Biol. Phys.54, 1485–1490 (2002).
- Fujimori K , CovellDG, FletcherJE, WeinsteinJN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med.31, 1191–1198 (1990).
- Thurber GM , SchmidtMM, WittrupKD. Factors determining antibody distribution in tumors. Trends Pharmacol. Sci.29, 57–61 (2008).
- Thurber GM , WittrupKD. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res.68, 3334–3341 (2008).
- Graff CP , WittrupKD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res.63, 1288–1296 (2003).
- Schmidt MM , WittrupKD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer. Ther.8, 2861–2871 (2009).
- Adams GP , SchierR, McCallAMet al. High affinity restricts the localization and tumor penetration of single chain Fv antibody molecules. Cancer Res. 61, 4750–4755.
- Verel I , HeiderKH, SiegmundMet al. Tumor targeting of antibodies with different affinity for target antigen CD44V6 in nude mice bearing head and neck cancer xenografts. Int. J. Cancer. 99, 396–402 (2002).
- Blumenthal RD . The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol. Immunother.33, 351 (1991).
- Wittrup KD . Tumor-targeting theory – kinetic and diffusive processes that determine antibody macro and microdistribution. Presented at: The Biorbis Antibody Engineering and Design Conference. Boston, MA, USA, 28–29 July 2010.
- Scott AM , LeeFT, JonesRet al. Phase I biopsy-based study of humanized monoclonal antibody A33 in patients with colorectal carcinoma. Clin. Cancer Res. 11, 4810–4817 (2005).
- Baxter LT , ZhuH, MackensenDG, ButlerWF, JainRK. Biodistribution of monoclonal antibodies, scale up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res.55, 4611–4622 (1995).
- Parulekar WR , EisenhauerEA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J. Natl Cancer Inst.96, 990–997 (2004).
- Shak S . For the Herceptin Multinational Investigator Study Group. Overview of the trastuzumab (Herceptin®) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin. Oncol.26(Suppl. 12), 71–77 (1999).
- Maloney DG , LilesTM, CzerwinskiDKet al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84, 2457–2466 (1994).
- Lockhart AC , BraunRD, YuDet al. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res. 9, 586–593 (2003).
- Maheswaren S , SequistL, NagrathSet al. Detection of mutations in EGFR in circulating lung-cancer cells. New Engl. J. Med. 359, 366–377 (2008).
- Herbertson RA , TebbuttNC, Lee F-T et al. Phase I biodistribution of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin. Cancer Res.15, 6709–6715 (2009).
- Joshi A , BauerR, KueblerP. et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J. Clin. Pharmacol.46, 10–20 (2006).
- Orlova A , TolmachevV, PehrsonRet al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 67, 2178–2186 (2007).
- Stumpp MT , AmstutzP. DARPins: a true alternative to antibodies. Curr. Opin. Drug Discov. Devel.10, 153–159 (2007).
- Kelly MP , LeeFT, TahtisKet al. Tumor targeting by multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother. Radiopharm. 23, 411–423 (2008).
- Chen C , BeckmanRA. Optimal cost-effective Go–No-Go decisions in late stage oncology drug development. Stat. Biopharm. Res.1, 159–169 (2009).